MCQ Quiz: Urinary Incontinence

Urinary incontinence (UI) is a common and often distressing condition that significantly impacts a patient’s quality of life. Effective management, a key topic in the “Urological Disorders” module of the Patient Care 5 curriculum, depends on correctly identifying the type of incontinence—be it stress, urge, or overflow. This quiz will test your knowledge of the pathophysiology, non-pharmacologic interventions, and the pharmacotherapy of urinary incontinence, with a focus on anticholinergic agents and beta-3 agonists used to treat overactive bladder.

1. A patient reports leaking urine when they cough, sneeze, or laugh. This is characteristic of which type of urinary incontinence?

  • a. Urge incontinence
  • b. Stress incontinence
  • c. Overflow incontinence
  • d. Functional incontinence

Answer: b. Stress incontinence

2. Urge incontinence, the primary symptom of Overactive Bladder (OAB), is caused by:

  • a. An underactive detrusor muscle.
  • b. A blockage at the bladder outlet.
  • c. Involuntary contractions of the detrusor muscle.
  • d. A weak urethral sphincter.

Answer: c. Involuntary contractions of the detrusor muscle.

3. Which class of medications is considered first-line pharmacotherapy for Urge UI / Overactive Bladder?

  • a. Alpha-blockers
  • b. Beta-3 adrenergic agonists
  • c. Anticholinergic/antimuscarinic agents
  • d. Loop diuretics

Answer: c. Anticholinergic/antimuscarinic agents

4. What is the primary mechanism of action for anticholinergic agents like oxybutynin in treating OAB?

  • a. They stimulate beta-3 receptors to relax the bladder.
  • b. They block M3 muscarinic receptors on the detrusor muscle, causing it to relax.
  • c. They increase the tone of the urethral sphincter.
  • d. They block dopamine receptors.

Answer: b. They block M3 muscarinic receptors on the detrusor muscle, causing it to relax.

5. A patient taking immediate-release oxybutynin is most likely to complain of which side effect?

  • a. Diarrhea
  • b. Increased salivation
  • c. Dry mouth
  • d. Weight loss

Answer: c. Dry mouth

6. The “Management of Urinary Incontinence” is a specific lecture in which course?

  • a. PHA5787C Patient Care 5
  • b. PHA5104 Sterile Compounding
  • c. PHA5703 Pharmacy Law and Ethics
  • d. PHA5878C Patient Care 3

Answer: a. PHA5787C Patient Care 5

7. Mirabegron is an alternative to anticholinergics for OAB. What is its mechanism of action?

  • a. It is an M3 receptor antagonist.
  • b. It is a beta-3 adrenergic agonist that relaxes the detrusor muscle.
  • c. It is an alpha-1 antagonist.
  • d. It is a 5-alpha reductase inhibitor.

Answer: b. It is a beta-3 adrenergic agonist that relaxes the detrusor muscle.

8. What is the most important first-line, non-pharmacologic intervention for both stress and urge incontinence?

  • a. A low-fluid diet.
  • b. Pelvic floor muscle exercises (Kegel exercises).
  • c. Timed voiding every 30 minutes.
  • d. Use of absorbent pads.

Answer: b. Pelvic floor muscle exercises (Kegel exercises).

9. A patient with benign prostatic hyperplasia (BPH) who experiences dribbling and a weak stream is likely to have which type of incontinence?

  • a. Stress incontinence
  • b. Urge incontinence
  • c. Overflow incontinence
  • d. Functional incontinence

Answer: c. Overflow incontinence

10. Why are extended-release (ER/XL) formulations of anticholinergics often preferred over immediate-release formulations?

  • a. They are more effective.
  • b. They have a more favorable side effect profile, particularly less dry mouth.
  • c. They are cheaper.
  • d. They have a faster onset of action.

Answer: b. They have a more favorable side effect profile, particularly less dry mouth.

11. The management of BPH and urinary incontinence are topics within the Patient Care 5 curriculum.

  • a. True
  • b. False

Answer: a. True

12. A patient using an oxybutynin transdermal patch should be counseled that the patch:

  • a. Is less likely to cause dry mouth compared to the oral formulation.
  • b. Should be applied to the same site every time.
  • c. Should be changed every day.
  • d. Can be cut in half.

Answer: a. Is less likely to cause dry mouth compared to the oral formulation.

13. A patient with narrow-angle glaucoma should not be prescribed which medication for OAB?

  • a. Mirabegron
  • b. An anticholinergic agent like tolterodine
  • c. Tamsulosin
  • d. All of these are safe.

Answer: b. An anticholinergic agent like tolterodine

14. The primary treatment for overflow incontinence caused by BPH is:

  • a. An anticholinergic medication.
  • b. Treatment of the underlying BPH with an alpha-blocker or 5-alpha reductase inhibitor.
  • c. Pelvic floor muscle exercises.
  • d. A bladder training regimen.

Answer: b. Treatment of the underlying BPH with an alpha-blocker or 5-alpha reductase inhibitor.

15. A pharmacist counseling a patient on UI should first:

  • a. Recommend the newest medication available.
  • b. Try to determine the type of incontinence the patient is experiencing.
  • c. Recommend adult diapers.
  • d. Tell the patient the condition is untreatable.

Answer: b. Try to determine the type of incontinence the patient is experiencing.

16. “Introduction to Urological Disorders” is a lecture within the Patient Care 5 curriculum.

  • a. True
  • b. False

Answer: a. True

17. Mirabegron should be used with caution in which patient population?

  • a. Patients with hypotension.
  • b. Patients with severe, uncontrolled hypertension.
  • c. Patients with diabetes.
  • d. Patients with asthma.

Answer: b. Patients with severe, uncontrolled hypertension.

18. Which of the following is a behavioral therapy technique for OAB?

  • a. Bladder training (scheduled voiding with increasing intervals).
  • b. Urge suppression techniques.
  • c. Fluid management.
  • d. All of the above.

Answer: d. All of the above.

19. Which of the following drugs can exacerbate stress incontinence by causing relaxation of the urethral sphincter?

  • a. Pseudoephedrine
  • b. An alpha-blocker like prazosin
  • c. An anticholinergic
  • d. A beta-3 agonist

Answer: b. An alpha-blocker like prazosin

20. An active learning session on urological disorders is part of the Patient Care 5 course.

  • a. True
  • b. False

Answer: a. True

21. A patient with cognitive impairment who repeatedly falls on the way to the bathroom is experiencing what type of incontinence?

  • a. Stress
  • b. Urge
  • c. Overflow
  • d. Functional

Answer: d. Functional

22. Which anticholinergic agent is more selective for M3 receptors, potentially leading to fewer CNS side effects?

  • a. Oxybutynin IR
  • b. Tolterodine
  • c. Solifenacin and Darifenacin
  • d. Trospium

Answer: c. Solifenacin and Darifenacin

23. The pharmacist’s role in managing UI includes:

  • a. Recommending appropriate non-pharmacologic interventions.
  • b. Counseling on the side effects of medications.
  • c. Assessing for potential drug interactions.
  • d. All of the above.

Answer: d. All of the above.

24. An active learning session on urological disorders is part of which course?

  • a. PHA5787C Patient Care 5
  • b. PHA5163L Professional Skills Lab 3
  • c. PHA5781 Patient Care I
  • d. PHA5782C Patient Care 2

Answer: a. PHA5787C Patient Care 5

25. A patient complains of leaking urine with a sudden, intense need to void. This is the classic symptom of:

  • a. Stress UI
  • b. Urge UI
  • c. Overflow UI
  • d. Functional UI

Answer: b. Urge UI

26. Which medication for OAB is a beta-3 agonist?

  • a. Oxybutynin
  • b. Solifenacin
  • c. Tolterodine
  • d. Mirabegron

Answer: d. Mirabegron

27. The detrusor muscle of the bladder is primarily under the control of which part of the nervous system for contraction?

  • a. Sympathetic (adrenergic)
  • b. Parasympathetic (cholinergic)
  • c. Somatic
  • d. Central

Answer: b. Parasympathetic (cholinergic)

28. An active learning session on urological disorders is part of which course module?

  • a. Module 8: Urological Disorders
  • b. Module 1: Diabetes Mellitus
  • c. Module 3: Women’s Health
  • d. Module 6: Geriatrics

Answer: a. Module 8: Urological Disorders

29. The main advantage of mirabegron over anticholinergic agents is:

  • a. It is more effective.
  • b. It is cheaper.
  • c. It lacks anticholinergic side effects like dry mouth and constipation.
  • d. It is dosed once a week.

Answer: c. It lacks anticholinergic side effects like dry mouth and constipation.

30. The management of BPH and UI is a lecture within the Patient Care 5 curriculum.

  • a. True
  • b. False

Answer: a. True

31. Which of the following is a common cause of overflow incontinence?

  • a. A weak detrusor muscle.
  • b. A bladder outlet obstruction (e.g., BPH).
  • c. Both a and b.
  • d. Neither a nor b.

Answer: c. Both a and b.

32. A patient with dementia is prescribed oxybutynin IR for urge incontinence. The pharmacist should be concerned about:

  • a. Worsening cognitive function.
  • b. The risk of hypertension.
  • c. The risk of diarrhea.
  • d. The patient developing a cough.

Answer: a. Worsening cognitive function.

33. What is the role of a bladder diary in the management of UI?

  • a. To track medication costs.
  • b. To help characterize the type and severity of incontinence by tracking fluid intake, voiding times, and leakage episodes.
  • c. It has no role in management.
  • d. To monitor for side effects only.

Answer: b. To help characterize the type and severity of incontinence by tracking fluid intake, voiding times, and leakage episodes.

34. The primary treatment for functional incontinence is:

  • a. An anticholinergic drug.
  • b. Mirabegron.
  • c. Addressing the underlying functional limitation (e.g., scheduled toileting, bedside commode).
  • d. A diuretic.

Answer: c. Addressing the underlying functional limitation (e.g., scheduled toileting, bedside commode).

35. An onabotulinumtoxinA (Botox) injection into the detrusor muscle is a third-line treatment option for:

  • a. Refractory urge incontinence / OAB.
  • b. Stress incontinence.
  • c. Overflow incontinence.
  • d. Functional incontinence.

Answer: a. Refractory urge incontinence / OAB.

36. A patient reports that their urine leaks constantly without any sensation of needing to void. This is most suggestive of:

  • a. Stress UI
  • b. Urge UI
  • c. Overflow UI
  • d. Mixed UI

Answer: c. Overflow UI

37. Which of the following medications can worsen UI by causing sedation and delirium, especially in the elderly?

  • a. Benzodiazepines
  • b. Opioids
  • c. First-generation antihistamines
  • d. All of the above

Answer: d. All of the above

38. The lecture “Management of BPH and Urinary Incontinence” is part of which course?

  • a. PHA5787C Patient Care 5
  • b. PHA5163L Professional Skills Lab 3
  • c. PHA5781 Patient Care I
  • d. PHA5782C Patient Care 2

Answer: a. PHA5787C Patient Care 5

39. Before starting pharmacotherapy for OAB, a trial of what is recommended?

  • a. A high-fluid diet.
  • b. Behavioral therapy for at least 4-6 weeks.
  • c. A stimulant laxative.
  • d. An antidepressant.

Answer: b. Behavioral therapy for at least 4-6 weeks.

40. An active learning session covering urological disorders is part of which course?

  • a. PHA5787C Patient Care 5
  • b. PHA5163L Professional Skills Lab 3
  • c. PHA5781 Patient Care I
  • d. PHA5782C Patient Care 2

Answer: a. PHA5787C Patient Care 5

41. The anticholinergic burden is a significant concern when treating UI in which patient population?

  • a. Pediatric patients
  • b. Young adults
  • c. Geriatric patients
  • d. Pregnant patients

Answer: c. Geriatric patients

42. Which of the following is a non-pharmacologic strategy for managing UI?

  • a. Limiting caffeine and alcohol intake.
  • b. Timed voiding.
  • c. Weight loss in overweight patients.
  • d. All of the above.

Answer: d. All of the above.

43. A pharmacist’s role in the management of UI is limited to dispensing medications.

  • a. True
  • b. False

Answer: b. False

44. Which alpha-agonist is sometimes used off-label to treat stress incontinence by increasing urethral sphincter tone?

  • a. Clonidine
  • b. Prazosin
  • c. Pseudoephedrine
  • d. Tamsulosin

Answer: c. Pseudoephedrine

45. The pathophysiology of stress incontinence involves weakness of the:

  • a. Detrusor muscle
  • b. Abdominal muscles
  • c. Pelvic floor muscles and urethral sphincter
  • d. Ureters

Answer: c. Pelvic floor muscles and urethral sphincter

46. A patient has both symptoms of stress and urge incontinence. This is known as:

  • a. Overflow incontinence
  • b. Functional incontinence
  • c. Mixed incontinence
  • d. Total incontinence

Answer: c. Mixed incontinence

47. Counseling on the management of UI is part of the Patient Care 5 curriculum.

  • a. True
  • b. False

Answer: a. True

48. An active learning session on urological disorders is part of which course module?

  • a. Module 8: Urological Disorders
  • b. Module 1: Diabetes Mellitus
  • c. Module 4: Medication Safety
  • d. Module 6: Geriatrics

Answer: a. Module 8: Urological Disorders

49. The overall management of urinary incontinence should be:

  • a. A “one-size-fits-all” approach.
  • b. Focused only on pharmacotherapy.
  • c. Individualized based on the type of UI and patient-specific factors.
  • d. Handled only by a urologist.

Answer: c. Individualized based on the type of UI and patient-specific factors.

50. The ultimate goal of learning about the management of urinary incontinence is to:

  • a. Help patients improve their quality of life by providing safe and effective treatment strategies.
  • b. Memorize all the brand names of anticholinergic drugs.
  • c. Pass the final exam.
  • d. Convince all patients to have surgery.

Answer: a. Help patients improve their quality of life by providing safe and effective treatment strategies.

Leave a Comment